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Abstract
Tuberculosis (TB), a major disease of public health importance, continues to cause signifi-
cant morbidity and mortality to populations around the world. In 2016, it accounted for 
1.7 million deaths worldwide. While the mortality rate among patients undergoing TB 
treatment has been declining over the years, TB death rates remains high in developing 
countries. This chapter discusses the epidemiology of TB mortality, the pathogenesis of 
TB highlighting susceptibility to mortality, and the interaction of factors which determine 
an individual’s risk to death on account of TB. Furthermore, the chapter proposes the 
need for a strategic research agenda on reduction of TB burden, focusing on the factors 
that enable or impede political will towards translating knowledge into effective action.
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1. Introduction
Tuberculosis (TB) remains a disease of public health importance affecting vulnerable popula-
tions. TB is the leading cause of death from a single infectious agent worldwide. The burden 
of the disease is enormous with an estimated 10.4 million new cases and 1.7 million TB deaths 
reported in 2016. Furthermore, more than one-fifths of reported deaths occurred among 
those who were HIV-infected [1]. While TB-mortality rate among HIV-negative people was 
17 per 100,000 population, it was 5 per 100,000 among people living with HIV. In addition, 
12% of incident cases of TB occurred among HIV-positive people while one in ten of new 
TB cases occurred among children in the same year [1]. According to WHO, the 30 countries 
most affected by TB include Angola, Bangladesh, Brazil, Cambodia, China, Congo, Central 
African Republic, DPR Korea, DR Congo, Ethiopia, India, Indonesia, Kenya, Lesotho, Liberia, 
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Mozambique, Myanmar, Namibia, Nigeria, Pakistan, Papua New Guinea, Philippines, Russian 
Federation, Sierra Leone, South Africa, Thailand, UR Tanzania, Viet Nam, Zambia, and 
Zimbabwe [1].
TB mortality burden is continues to pose challenges to socioeconomic development in devel-
oping countries as South East Asia, Western Pacific, and African regions accounted for more 
than 90% of TB-deaths in 2016 [1].
Analysis of cohorts of patients on tuberculosis treatment enables public health programmes 
to describe the survival of patients and factors associated with mortality experience among 
patients. While treatment outcomes vary among different cohorts of TB patients, patients 
with drug resistance TB and those with coexisting debilitating conditions experience worst 
outcomes. Furthermore, survival of TB patients depends on several medical, demographic 
and socio-economic factors. This chapter focuses on the epidemiology of TB mortality, and 
the determinants of survival of TB patients – the factors which represent the most important 
opportunities for prevention of TB-related deaths in developing countries.
2. Epidemiology of TB mortality
Mycobacterium tuberculosis––the causative organism of TB, is the leading cause of death from 
a single infectious agent after Human Immunodeficiency Virus (HIV). About 45,000 TB-related 
deaths occurred in Europe in 2011 and its estimated mortality rate was 5.0 per 100,000 popu-
lation [2]. While 330 TB-related deaths and an estimated TB-mortality rate of 0.5 per 100,000 
population were reported in the United Kingdom, TB-death rates were 0.4, 1.0, 8.9, 15.0, and 
16.0 per 100,000 population in Germany, France, Belarus, Russia, and Ukraine respectively 
[3]. In the United States, more than 50,000 TB-related deaths were reported from 1990 to 2006, 
accounting for 0.13% of the total number of deaths in the country [4]. While TB was reported as 
the underlying cause of death in about 40% of the 39,694,210 total deaths that occurred, it was 
reported as one of the contributing causes of death in more than 60% of the total deaths [1]. 
The overall mean annual mortality rate was 1.16 per 100,000 person-years during this period 
[1]. Similarly, 7% of the 301 persons with TB reported to Connecticut TB Control Program from 
2007 to 2009 died on account of the disease [5]. Furthermore, 11% of the 40, 125 patients with 
culture-confirmed TB died on account the disease in California from 1994 to 2008 [3]. In 2014, 
more than 5% of the 9406 patients with TB in the US died due to the disease [6].
Although TB is a major public health problem worldwide, its mortality in developing coun-
tries is alarming. An estimated 2.5 million TB deaths were reported in China from 1990 to 2015 
and 2% of these deaths occurred in 2015 [7]. Furthermore, TB-mortality rates were 32 and 44 
per 100,000 population in 2016 in India and Pakistan, respectively [1]. While 16% of those 
who had TB died of the disease in Zimbabwe was in 2013 [8], TB-related mortality rates were 
estimated at 29, 56, 83, 104, and 222 per 100,000 population in Ethiopia, Ghana, Swaziland, 
Nigeria, and South Africa respectively in 2016 [1]. In addition, the estimated TB-related mor-
tality rate in in Africa was 72 per 100,000 population while it was 3.4 per 100,000 population 
in European region and 2.3 per 100,000 population in the WHO Region of the Americas in 
2016 [1].
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2.1. Global trends in TB mortality
Tuberculosis, often referred to as “consumption,” “phthisis,” or the “white plague,” accounted 
for the highest number of deaths in Europe and America during the eighteenth and nine-
teenth centuries. While 70–90% of urban populations of Europe and North America were 
infected with TB in the late nineteenth century, four-fifths of people infected with TB died 
of it [9]. Through the knowledge made available by the work of Villemin, Koch, von Pirquet, 
TB mortality began to decline in the early and mid-nineteenth century [10–12]. TB Decline in 
TB mortality in these parts of the world was associated with improvement in socio-economic 
conditions of the populations.
In the United Kingdom, the rapid decline in TB mortality was cited as one of the most impor-
tant health gains of the twentieth century [13]. Using all certified causes of death (both under-
lying cause and elsewhere on certificates), TB-mortality in the Oxford region declined from 
39.7 deaths per million population in 1979 to 9.0 in 2008. In England, TB-mortality rates fell 
from 18.5 per million population in 1995 to 12.2 in 2008 [13].
TB mortality has been dropping rapidly since 1900 in developed countries, especially after the 
development of new anti-tuberculosis drugs. In the United States, 74,842 TB-related deaths 
were reported in 1933 [14]. This had declined by 22.9% by 1942 and a further decline was 
reported in the following decade such that only 25,080 TB-related deaths were reported in 1952 
[12]. Furthermore, TB-mortality rates were 59.6, 43.1, and 16.1 per 100, 000 population in 1933, 
1942, and 1952 respectively in the United States [12]. While 644 TB-deaths were reported in 
2006, the estimated number of TB-related deaths was 610 in 2016 [1]. In essence, TB-mortality 
declined in the US from 59.6 per 100, 000 in 1933 to 0.19 per 100, 000 in 2016 [1, 12].
Due to poor vital registration systems, records on TB-mortality trends in developing countries 
are limited. A significant increase in TB mortality was recorded from 1990 and 2000 world-
wide. However, the increase was more obvious in developing countries (Figure 1). In 2004, 
TB-mortality rate in Bangladesh was 51 per 100,000 population, while it was 81 per 100,000 in 
2014 [8, 15]. Similarly, TB-death rates in Nigeria and South Africa in 2004 were 82 and 135 
Figure 1. Global trends in TB mortality from 1990 to 2000. Data source: Global tuberculosis report 2013. WHO/HTM/
TB/2013.11. Geneva: WHO; 2013.
Determinants of Survival of Patients with Tuberculosis in Developing Countries
http://dx.doi.org/10.5772/intechopen.75890
55
per 100,000 population respectively. By 2014, the mortality rates had increased to 170 per 
100,000 in Nigeria while it decreased to 24 per 100,000 in South Africa [7, 14]. Furthermore, TB 
mortality rates declined significantly between 2000 and 2016 (Figure 2).
3. Pathogenesis of TB infection
Tuberculosis (TB) is an old disease of mankind from time immemorial. An evidence of TB 
spine was found in Egyptian mummies of several thousand years BC, while Babylonian 
and Chinese writings also referred to the disease [16]. TB is an infection caused by the rod-
shaped, non-spore-forming bacterium called Mycobacterium tuberculosis, a member of a group 
called M. tuberculosis complex (MTBC). Other members of this complex include M. bovis, 
M. microti, M. africanum, M. caprae, M. canetti and M. pinnipedii. MTBC members are closely 
related genetically. The genome of M. bovis differs from that of M. tuberculosis by less than 
0.05% [17]. While M. bovis primarily affects cattle, it can also TB disease in other mammals 
include man [18].
TB infection leads to a complex interaction with the immune system of the human host. This 
interaction is often moderated by a number of factors with influence survival of TB patients.
Figure 2. Global trends in TB mortality from 2000 to 2016. Data source: WHO. Global Health Observatory data repository. 
Tuberculosis [Internet]. Geneva: WHO; 2017 Dec 1 [cited 2018 Feb 12]. Available from: http://apps.who.int/gho/data/
node.main.1315?lang=en.
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3.1. Transmission
TB is transmitted from a person with active TB disease to an uninfected person through the 
air by droplet nuclei––particles measuring 1–5 μm in diameter containing MTBC [19]. These 
droplet nuclei are produced when persons with pulmonary or laryngeal TB cough, sneeze, 
speak, or sing. Iatrogenic transmission of TB may also occur during aerosol treatments, spu-
tum induction, bronchoscopy, or during tissue or secretion processing in hospitals or labo-
ratories. Droplet nuclei can remain airborne for long periods of time after expectoration. The 
transmission of TB depends on a number of factors including the number of tubercle bacilli 
present in droplets, its virulence and exposure to ultraviolet light, the extent of ventilation, 
and the immune status of exposed persons. After inhalation of an infectious droplet nucleus, 
it settles in the respiratory tract and reaches a respiratory bronchiole or alveolus where the 
tubercle bacilli may establish an infection depending on the bacterial virulence and the inher-
ent mycobactericidal capacity of the alveolar macrophage. With the activation of the host 
defenses, phagocytosis by alveolar macrophages often initiates a cascade of events resulting 
in either a successful control of the infection, which is usually followed by latent tubercu-
losis. The invading mycobacterium may overwhelm host defense mechanisms followed by 
progression to active disease, known as primary progressive tuberculosis [19]. Within the 
alveolar macrophage, the tubercle bacillus continues growing slowly and dividing almost 
every 25–32 h for 2–12 weeks such that they reach 103–104 thereby eliciting a cellular immune 
response which is often detected by a positive reaction to a tuberculin test. For an immuno-
competent person, the formation of granulomas around the invading mycobacterium occurs 
at this time.
Prior to the development of cellular immunity, tubercle bacilli may be disseminated via the 
lymphatics to the hilar lymph nodes and the bloodstream. When these bacilli reach more dis-
tant sites, they may give rise to extra pulmonary TB infection of the brain meninges, larynx, 
lymph nodes, spine, and kidney.
3.2. Pathophysiology
Granulomas formed by accumulation of T lymphocytes and microphages limit mycobacterial 
replication and spread [20]. Although the environment provided by granuloma formation 
destroys macrophages and produces early solid necrosis at the center of the lesion, tuber-
cle bacilli often adapt to enhance their survival [20]. The formation of caseous necrosis, a 
soft-cheese structure with low oxygen levels, low pH, and limited nutrients in the following 
2–3 weeks creates a condition that limits further mycobacterial growth. Latent tuberculosis is 
established at this stage. While tuberculous lesions undergo fibrosis and calcification thereby 
controlling the infection, the tubercle bacilli within the lesions may begin to multiply rapidly 
if the immune system of the individual deteriorates [21].
For an immunocompromised person, granuloma formation also occurs following infection 
with MTBC. However, the granulomas formed are unable to contain the infection. Hence, this 
progresses to primary progressive tuberculosis [21]. The necrotic tissue of the granuloma lique-
fies and the fibrous wall breaks down. Furthermore, the semiliquid necrotic matter may drain 
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into surrounding structures including the bronchi, and nearby blood vessels leaving an empty, 
air-filled cavity at the middle of the initial lesion. In addition, discharge of the necrotic material 
into a vessel may lead to extra pulmonary TB and mortality from TB may be related to this.
4. Factors associated with survival among TB patients in developing 
countries
The management of patients suspected of TB disease involves clinical assessment and treat-
ment (Figure 3). Of the treatment outcomes, Cured and Completed treatment are considered 
as successful outcomes while the remaining ones are often referred to as poor treatment out-
comes [1, 22].
Although deaths on account of TB disease occur worldwide, developing countries account 
for more than 90% of TB mortality in recent times. Hence, the focus of this section will be on 
developing countries. Several factors influence susceptibility of TB infection, its severity as 
well as mortality.
Factors associated with survival among TB patients in developing countries can be discussed 
using a framework proposed by the Commission on Social Determinants of Health (CSDH) 
established by WHO (Figure 4) [23].
Factors associated with survival among patients with TB disease can be classified into patient 
and community/social factors. In the context of the CSDH framework, most of the patient fac-
tors can be described in terms of the health system while community/social factors are related 
to the structural determinants of health and health inequities. Patient characteristics include 
age, sex, alcohol use, cigarette smoking, previous history of TB treatment, HIV co-infection, 
and comorbid conditions, TB diagnostic methods, and treatment regimens. On the other 
hand, structural determinants of health associated with TB survival include the presence of 
education, employment, access to health care and protection from catastrophic expenditure 
associated with TB morbidity.
4.1. Age
Aging affects the immune system at multiple levels including reduced production of B and T cells 
and diminished function of mature lymphocytes in secondary lymphoid tissues. Furthermore, 
aging causes a profound alteration in the composition and quality of the mature lymphocyte 
pool and alters the patterns of gene expression in mature B and T cells. Compared to young 
people, elderly individuals respond to immune challenge in a less efficient manner [24].
Old age increases the likelihood of death from TB. Evidence for this has been reported in 
previous studies. While several age cut-points have been used in studies to show vulnerabil-
ity, TB infection in people over the age of 60 years is associated with increased mortality. A 
retrospective study among adult patients with clinically and/or bacteriologically diagnosed 
TB in Argentina reported increased mortality among people who were older than 50 years 
[22]. A similar study conducted in South Africa reported that patients who were 60 years or 
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older were twice more likely to die from TB than the younger ones [25]. In addition, patients 
aged 65 years and above were two times more likely to die from TB than other patients in a 
study in Zimbabwe [26].
4.2. Sex
Infectious diseases including TB generally affect males more than females. Studies have 
shown that interactions between sex hormones and the immune system render males more 
Figure 3. Clinical assessment and treatment of TB patients.
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susceptible to infection and disease, with differences in genetic make-up likely playing a role 
[27, 28].
A recent study in Brazil aimed at examining sex bias in ten major pathogens also reported the 
characteristic male bias of a male-to-female ratio of almost 2:1 [2]. While tuberculoid leprosy 
is slightly more common in females (0.85:1), the study reported a ratio of almost 3:1 for the 
severe lepromatous form. Host immune response to leprosy has been compared to that in 
tuberculosis and lepromatous leprosy was considered as being analogous to active tubercu-
losis. Furthermore, tuberculoid leprosy may be seen as analogous to latent TB or cured or TB 
[29]. Since both diseases are caused by the same pathogen—Mycobacterium, the male bias 
observed supports the hypothesis that physiological differences may be responsible for the 
observed differential susceptibility to TB. This physiological hypothesis (PH) has also been 
found to be relevant in TB disease as a driver of sex differences in disease susceptibility [1, 2]. 
TB mortality is also in keeping with differential susceptibility between males and females 
as more than 65% of adult TB deaths in 2016 occurred among males [1]. This is also similar 
to the twentieth century in New York which showed a male-to-female TB mortality ratio of 
approximately 2:1 [30].
A consistent finding in literature shows that males are more likely to die from tuberculosis 
than females. A study in Ethiopia, showed that males are twice more likely to have poor 
treatment outcome (including death) following TB treatment [31]. In addition, a systematic 
review and meta-analysis consisting of multidrug resistant-TB (MDR-TB) data from 31 treat-
ment programmes from 21 countries showed that males are less likely to have a successful 
outcome after treatment [32]. Although there was no association between sex and survival 
among patients in a study in South Africa, male patients were more likely to have unfavorable 
TB treatment outcomes [33].
Figure 4. Conceptual framework for the social determinants of health and health inequities [23].
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4.3. Education
Educational status is an important factor which moderates health care seeking behavior and 
adherence to prescribed medications. The level of educational achievement may protect 
against acquiring TB infection through promotion of healthy habits. In addition, education 
been recognized as a marker of economic status. Hence, low level education may be associ-
ated with lack of access to resources, overcrowding and poor hygienic conditions which may 
also contribute to increased mortality. In a study in Peru, MDR-TB patients who attended for-
mal school for 6 or less years had about threefold increase in TB mortality risk [34]. Similarly, 
attendance or completion of primary school level was associated with TB treatment failure 
[35]. While educational status may be a significant factor influencing survival in most health 
conditions, only a few studies reported it as a determinant of survival among patients with 
TB in developing countries [32, 34].
4.4. Occupation
Occupations which compromise structural and/or functional integrity of the lungs predispose 
individuals to the transmission of TB as well as to higher risk of mortality on account of the 
disease. While exposures to dust inside the mines damage the structure and function of the 
lungs (e.g., silicosis), associated social conditions outside the mines (e.g., crowding) drive HIV 
and TB epidemics. This makes mining a strong predictor of TB mortality. Studies in Southern 
Africa have reported the strong association between mining and TB mortality [36, 37].
4.5. Smoking
Smoking is one of the most important risk factors associated with incidence, morbidity, recur-
rence and mortality from TB. Smoking has been associated with a fourfold increase in TB 
mortality risk [38].
4.6. Previous history of TB treatment
Previous TB treatment has been associated with TB mortality. A prospective study among 
smear positive TB patients with Iranian nationality who had successful TB treatment 
showed that those who had previous history of TB treatment were almost three times more 
likely to die [39]. Similarly, patients with a previous history of TB treatment were almost 
seven times more likely to die than treatment-naive patients in another study in Iran [40]. 
This may be related to development of resistance following treatment default, failure, or 
loss to follow up.
4.7. Type of TB strain
Multidrug-resistant tuberculosis (MDR-TB), a form of TB disease resistant to both isoniazid 
and rifampicin is a global problem. Increasing incidence of this type of TB is a reflection of 
the health care system of a country. It arises as a result of weak TB treatment programmes 
coupled with poor adherence to anti-TB therapy. While the extent and burden of the disease 
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varies among countries, it often overwhelms the capacity of the health system in many high 
burden resource-poor countries.
Studies have consistently shown that MDR-TB is a strong predictor of TB mortality. In 2016, it 
was responsible for a large percentage of TB mortality worldwide [1]. MDR-TB was associated 
with almost eightfold increase in mortality risk in a retrospective study in Peru [32]. Other 
studies have also shown similar findings. Furthermore, MDR-TB associated hazard ratio (HR) 
estimates in TB mortality increase in previous studies were in the range of 7.8–8.5 [41, 42].
Extensively drug-resistant tuberculosis (XDR-TB), a variant of MDR-TB resistant to any fluo-
roquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, 
or capreomycin) in addition to isoniazid and rifampin. XDR-TB has also been associated with 
high death rates while on treatment.
There are multiple causes for the increased risk of multidrug-resistant TB strains. MDR-TB 
infection often occur with other co-morbid conditions including HIV infection, diabetes, renal 
disease, and Substance Use Disorders [43]. In addition, MDR-TB has been associated with 
high rates of treatment failure and relapse which increases TB mortality. With high toxicity of 
anti-tuberculosis drugs used in the treatment of MDR-TB and the extended duration of use, 
an increase in toxicity profile of patients and consequent adverse effects may be related to 
increased mortality experienced among MDR-TB patients.
4.8. HIV co-infection
Studies have shown that HIV/TB co-infection is associated with increased TB mortality risk 
before, during, or after TB treatment. In most cases, deaths are usually caused by complica-
tions of HIV infection rather than TB disease itself. However, a synergistic interaction occurs 
between TB and HIV infection which speeds up the progression of illness and increasing mor-
tality risk. HIV infection enhances the reactivation and progression of latent Mycobacterium 
tuberculosis to active TB disease, and the active TB disease accelerates HIV disease progression 
in infected patients. Furthermore, HIV infection alters the clinical presentation of TB and com-
plicates TB treatment follow-up [44].
In Malawi, HIV positive patients were 2.5 times more likely to die from TB infection in a pro-
spective cohort study among TB patients [45]. Another study in Malawi also reported almost 
fourfold increase in TB mortality among HIV/TB co-infected patients compared to HIV sero-
negative TB patients [46]. Furthermore, HIV co-infection was associated with almost sixfold 
increase in TB mortality in a study in Ethiopia [35].
Among patients who were HIV/TB co-infected, being on antiretroviral therapy (ART), initia-
tion of cotrimoxazole prophylactic therapy (CPT), being ambulatory, and having high CD4 
counts were factors associated with survival in several studies. Patients who were on ART 
were 0.35 times less likely to die from TB compared to those who were not on ART [47].
While MDR-TB infection is associated with increased mortality risk for both HIV-seropositive 
and seronegative patients, HIV/MDR-TB co-infection increases the risk of death. A study 
in Thailand reported that patients who were HIV positive patients infected with MDR-TB 
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were twice more likely to die compared to HIV seropositive patients who had non-MDR-TB 
co-infection [48]. Similarly, HIV/TB co-infected patients who delayed initiation of ART 6 or 
months or more after TB diagnosis were 2.6 times more likely to die compared with those who 
initiated ART in less than 6 months following TB diagnosis [47].
4.9. Extra pulmonary TB
Although extra pulmonary TB is not as common as pulmonary disease, its occurrence has 
consistently been shown in literature as a predictor of TB mortality. Patients with extra pul-
monary TB including TB meningitis, TB pericarditis, TB peritonitis, bilateral or extensive 
pleural effusion due to TB, Potts disease, TB of the genitourinary tract, and TB of the intestine 
were twice more likely to die on account of the disease than patients with pulmonary disease 
in a study in Brazil [49]. Furthermore, patients who had extra pulmonary TB were three times 
more likely to die than those who had pulmonary TB [50]. Similarly, miliary TB has also been 
associated with poor outcomes [51].
4.10. Co-morbid conditions
Co-morbid conditions including malnutrition, chronic renal disease, chronic liver disease, 
drug induced immunosuppression, and diabetes mellitus are predictors of mortality among 
TB patients.
4.10.1. Diabetes
The synergistic interactions between diabetes mellitus and TB are well documented in litera-
ture [52]. Diabetes alters host immunity to TB which leads to higher baseline mycobacterial 
burdens and longer times to achieve culture conversion with treatment. While treatment fail-
ure or death was reported in 41% of patients with TB and diabetes in case-control study, these 
outcomes were only reported in 13% of those with TB alone. Furthermore, seven of the eight 
patients in the TB and diabetes group died of respiratory failure related to TB [53].
4.10.2. Malnutrition
Malnutrition has been cited as a predictor of mortality among TB patients. Malnourished 
patients were 27 times more likely to have unfavorable TB outcome and death in a study in 
South Africa [54].
4.10.3. Chronic renal disease
The presence of end stage renal disease requiring dialysis was associated with sevenfold 
increase in TB mortality risk in a previous study [55].
4.10.4. Drug-induced immunosuppression
The presence of drug induced immunosuppression was associated with increased TB mortal-
ity risk with adjusted odds ratio of 3.2 [51].
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4.11. Poor adherence to anti-Koch therapy
Studies have shown that TB patients with poor adherence to medications are more likely 
to die compared to other patients. A retrospective study involving patients in 48 clinics in 
Rwanda among patients treated in 48 clinics in Rwanda showed that poor treatment adher-
ence was associated with more than threefold increase in TB mortality [56].
4.12. Neighbourhood and social factors
Neighbourhood factors refer to issues within the society that contribute to TB mortality which 
are not directly related to a patient’s individual condition but a constellation of factors which 
affect a patient’s access to care, treatment enablers, emergency services, and attitudes of the 
general population to health. These include societal norms and values, policy, and gover-
nance issues within and outside the health system (Figure 4).
Neighbourhoods play a role in TB morbidity and mortality as good housing may influence 
air quality and disease transmission. Access to nutritious foods may also be important for 
immune responses and recovery from TB infection. In addition, Service characteristics of 
neighbourhoods can create and support employment opportunities which may reinforce 
socioeconomic disparities in health.
The level of the commitment of health authorities at the local, regional, and national levels 
towards TB treatment, care and support influences the survival of patients [1]. For instance, 
the failure of a TB treatment programme to follow up on patients on treatment may contribute 
to increased mortality. In addition, failure of the health system to screen and test HIV positive 
patients for TB may also affect their survival.
Social protection is one of the functions of the health system. However, unemployment, low 
status occupation, low annual income, high cost of travel to the health care facility for TB 
treatment, poor living conditions, low literacy level, and high out-of-pocket expenditure on 
TB treatment have been described as factors associated with poor treatment adherence, unfa-
vorable TB treatment outcomes, and death. Furthermore, a strong correlation was reported 
between TB treatment outcomes and overall health system performance in a study in South 
Africa where TB treatment centers with higher health system performance rating also had 
higher percentage of successful treatment outcomes [57].
4.13. Climatic factors and TB seasonality
Studies have shown that seasonal variation in the incidence of TB disease occurs in many 
developing countries. In India and Hong Kong, TB seasonality was highest among young 
children. However, seasonality of notified TB cases was more pronounced among males in 
Mongolia and South Western Cameroon [58]. In Southern Africa, most significant declines in 
the diagnoses of pulmonary TB occurred in December, followed by April–May. While these 
may not be unrelated to climatic factors, changes in health-seeking behavior and fluctuations 
in clinical activities were cited as responsible factors [59]. In China, increased incidence of TB 
was associated with increased temperature, precipitation, and wind speed [60].
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Seasonality of TB disease may be related to differences in TB risk factors at certain seasons. A 
study in Peru showed the complex interaction of social determinants of TB infection, exposure 
to infection and increased transmission. Overcrowding, increased indoor time, and poorer 
ventilation, poorer nutrition, lower immunity, health-seeking behavior, and education inter-
act in a complex way to an increase in TB disease at certain seasons than others. Vitamin D 
deficiency, more likely to occur in winter, was also associated with TB seasonality [61].
5. Conclusion
The burden of TB and the mortality on account of the disease has been discussed. While dif-
ferences in mortality between population groups due to society’s characteristics have been 
noted, factors associated with reduced survival among TB patients have been highlighted. 
Furthermore, it is important to note that changes in social and cultural environments of peo-
ple are associated with changes in their risks of acquiring TB infection, and the risk of dying 
from the disease. Although associations between social factors and TB morbidity and mortal-
ity are well known, there is paucity of studies regarding the underlying processes linking 
social determinants and TB treatment outcomes and effective ways to intervene. While TB 
morbidity and mortality have reduced significantly in many parts of the third world in recent 
times, limited progress achievement are been recorded in other countries. A crucial obstacle 
in this regard is often the lack of political will. A strategic research agenda on reduction of TB 
burden should focus on the factors that enhance or impede political will to translate knowl-
edge into effective action.
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